Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515 Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

Secretary of the Senate Received: Feb 11, 2003

## **LOBBYING REPORT**

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

1. Registrant Name:
TONGOUR SIMPSON HOLSCLAW LYTLE, LLC
2. Address: 227 MASSACHUSETTS AVE NE    #1, WASHINGTON, DC 20002
Principal place of business (if different from line 2):
4. Contact Name: JOHN BRAD HOLSCLAW Telephone: 202-544-7600 E-mail (optional): holsclaw@tongoursimpson.com
Senate ID #: 51478-241 House ID #: 34927013
7. Client Name: Self
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA
TYPE OF REPORT
8. Year 2002 Midyear (January 1 - June 30): OR Year End (July 1 - December 31): 🗵
9. Check if this filing amends a previously filed version of this report:
10. Check if this is a Termination Report: => Termination Date: 11. No Lobbying Activity:
INCOME OR EXPENSES
Complete Either Line 12 <b>OR</b> Line 13
12. Lobbying Firms
INCOME relating to lobbying activities for this reporting period was:
Less than \$10,000:
\$10,000 or more: X => Income (nearest \$20,000): 80,000.00
Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to th registrant by any other entity for lobbying activities on behalf of the client).
13. Organizations
EXPENSES relating to lobbying activities for this reporting period were:
Less than \$10,000:
\$10,000 or more: => Expenses (nearest \$20,000):
14. Reporting Method. Check box to indicate expense accounting method. See instructions for description of options.
Method A. Reporting amounts using LDA definitions only Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code

Page 1

Registrant Name: TONGOUR SIMPSON HOLSCLAW LYTLE, LLC Client Name: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

## LOBBYING ACTIVITY.

Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Attach additional page(s) as needed.

- 15. General issue area code: PHA (one per page)
- 16. Specific lobbying issues:

1) S.2801 and H.R.5263, FY 2003 AG Appropriations. 2) S.812, Greater Access to Affordable Pharmaceuticals Act. 3) H.R.4954, Medicare Modernization Prescription Drug Act. 4) S.2729, 21st Century Medicare Act. 5) S.1229, Personal Prescription Drug Import Fairness Act.

17. House(s) of Congress and Federal agencies contacted: HOUSE OF REPRESENTATIVES SENATE

18. Name of each individual who acted as a lobbyist in this issue area:

Name: Holsclaw, Brad Covered Official Position (if applicable): N/A Name: TONGOUR, MICHAEL Covered Official Position (if applicable): N/A

19. Interest of each foreign entity in the specific issues listed on line 16 above. None

Signature: ON FILE Date: Feb 11, 2003

Printed Name and Title: JOHN BRAD HOLSCLAW - PARTNER